Sermorelin Missed-Dose Protocol: What to Do If You Skip an Injection

At a glance
- Drug / sermorelin acetate (GHRH analogue, 503A compounding)
- Route / subcutaneous injection, typically 100-300 mcg nightly
- Ideal timing / 30-60 minutes before sleep on an empty stomach
- Half-life / 10-20 minutes after subcutaneous injection
- Missed dose rule / skip it, resume next scheduled bedtime dose
- Double dosing / never recommended; risks GH receptor desensitization
- Mechanism / stimulates pituitary somatotrophs to release endogenous GH
- Onset of benefit / measurable IGF-1 changes within 3-4 weeks of consistent use
- Storage / refrigerate reconstituted vials at 2-8 degrees Celsius
- Prescription status / prescription-only via 503A compounding pharmacies
How Sermorelin Works and Why Timing Matters
Sermorelin acetate is a 29-amino-acid peptide identical to the first 29 residues of human growth hormone-releasing hormone (GHRH 1-29). It binds the GHRH receptor on anterior pituitary somatotroph cells and triggers the release of endogenous growth hormone in a pulsatile pattern that mimics normal physiology [1]. This is a fundamentally different mechanism from exogenous GH injections, which bypass the pituitary entirely and deliver a fixed bolus of recombinant hormone.
The distinction matters for missed-dose decisions. Because sermorelin prompts your own pituitary to secrete GH rather than providing the hormone directly, the consequences of one skipped dose are far less acute than missing a dose of exogenous somatropin. A 1999 pharmacologic review in BioDrugs noted that sermorelin "restores the normal pulsatile pattern of GH secretion" rather than creating supraphysiologic peaks [2]. Your pituitary will continue producing baseline GH pulses during sleep even without the sermorelin stimulus, though the amplitude of those pulses will be smaller.
Sermorelin's plasma half-life is short. After subcutaneous injection, the peptide is cleared in roughly 10 to 20 minutes [3]. That rapid clearance is why bedtime administration is standard: the peptide triggers a GH pulse that coincides with the largest natural GH secretory burst, which occurs during the first 90 minutes of slow-wave sleep [4]. Missing that window by injecting at midday or early afternoon produces a less physiologically meaningful response.
The Standard Missed-Dose Rule
Skip the missed dose. Resume your normal injection at bedtime the next night.
This guidance follows the same principle applied to most short-acting peptide therapies with once-daily dosing. The Endocrine Society's 2011 clinical practice guideline on adult GH deficiency, while written primarily for recombinant GH, states that patients who miss a dose of GH therapy should not take a double dose and should instead return to their regular schedule [5]. Sermorelin prescribers apply the same logic, with even more confidence, because the peptide is a secretagogue rather than the hormone itself.
Doubling a sermorelin dose introduces two risks. First, a supraphysiologic GHRH stimulus can trigger negative feedback at the hypothalamic level through increased somatostatin tone, which may actually blunt GH release for hours afterward [6]. Second, repeated high-amplitude GHRH pulses can downregulate the GHRH receptor on somatotroph cells, reducing your response to subsequent normal doses. Neither outcome is dangerous in a single instance, but both defeat the purpose of trying to "make up" the lost injection.
The clinical bottom line: one skipped night costs you one GH pulse. That loss is trivial over a treatment course measured in months.
Why Bedtime Dosing Is Non-Negotiable
The choice to inject sermorelin 30 to 60 minutes before sleep is not arbitrary. GH secretion follows a circadian rhythm anchored to sleep onset. Roughly 70% of daily GH output in healthy adults occurs during nocturnal slow-wave sleep, with the largest single pulse firing within the first 90 minutes after falling asleep [4]. Sermorelin timed to this window amplifies that natural surge.
A 1990 study by Walker et al. in GH-deficient pediatric patients demonstrated that sermorelin administered at bedtime produced significant increases in growth velocity over 12 months (P<0.05 vs. baseline), with the response correlating to the degree of residual pituitary function [7]. Patients whose somatotrophs retained some GHRH receptor density responded better, reinforcing that sermorelin's efficacy depends on a functioning (if underperforming) pituitary.
Injecting sermorelin in the morning or afternoon is less effective for three reasons. Somatostatin tone is higher during waking hours, which opposes GHRH signaling [6]. Cortisol, which peaks in the early morning, blunts GH secretion. Food intake within 60 to 90 minutes of injection can also suppress the GH response because postprandial hyperglycemia and elevated free fatty acids inhibit somatotroph activation [8]. If you realize you missed your bedtime dose after waking up the next morning, the correct move is to wait until that evening, not inject immediately.
What Happens Physiologically When You Miss a Dose
Your body does not stop making GH. It just makes less.
In a person with partial GH deficiency (the typical sermorelin candidate), the pituitary still produces GH pulses throughout the night. Sermorelin increases the amplitude of those pulses by 2- to 5-fold, depending on individual pituitary reserve [2]. Without the sermorelin stimulus, pulse amplitude drops back to the patient's untreated baseline. A single night at baseline GH output does not measurably change serum IGF-1 levels, which reflect integrated GH exposure over days to weeks rather than any single pulse.
Data from GH secretagogue studies support this. In a trial of another GHRH analogue (tesamorelin) in HIV-associated lipodystrophy, IGF-1 levels remained stable when measured across weekly intervals despite expected day-to-day variation in individual GH pulses [9]. The takeaway: your IGF-1 trajectory (the metric most clinicians track) is determined by weeks of consistent dosing, not by any one night.
Missing two or more consecutive doses begins to have a measurable effect. Three consecutive missed doses can lower mean nocturnal GH output enough to start pulling IGF-1 downward within 5 to 7 days, based on the known half-life of IGF-1 (approximately 12 to 15 hours for free IGF-1 and 12 to 15 days for the IGFBP-3 bound fraction) [10]. If you miss more than two nights in a row, contact your prescriber. The solution is still not to double dose. It is to resume nightly injections and, if needed, recheck IGF-1 at your next scheduled lab draw.
Factors That Affect How Much a Missed Dose Matters
Not every patient loses the same amount of GH stimulus from one skipped injection. Several variables influence how consequential that missed dose actually is.
Pituitary reserve. Patients with higher residual somatotroph function produce more GH independently. For these individuals, a missed sermorelin dose has even less impact because their baseline nocturnal pulses are already partially preserved. Walker et al. showed that children with greater pituitary reserve achieved better growth velocity responses, suggesting their GH axis was more strong at baseline [7].
Age. GH secretion declines with age at an estimated rate of 14% per decade after age 30 [11]. An older patient with a lower baseline GH output may feel the subjective effects of a missed dose (slightly poorer sleep quality, for instance) more than a younger patient. The objective hormonal impact remains small for a single missed night.
Body composition. Higher visceral adiposity is associated with reduced GH pulse amplitude through increased somatostatin tone and elevated free fatty acid levels [8]. Patients with obesity may already be operating at a lower GH baseline, making each sermorelin-stimulated pulse proportionally more important. This is a reason to maintain dosing consistency, not a reason to double up after a miss.
Concurrent medications. Glucocorticoids suppress GH secretion. Patients on even low-dose prednisone (5 to 7.5 mg daily) may have blunted sermorelin responses, making consistent dosing more valuable [5]. If you are taking a corticosteroid and miss a sermorelin dose, the priority is simply to return to your schedule the following night.
Practical Tips to Avoid Missing Doses
The most common reason patients miss a sermorelin injection is forgetting. The second most common reason is travel logistics around cold-chain storage. Both are preventable.
Set a recurring alarm for 30 to 60 minutes before your typical bedtime. Place the alarm label with a specific instruction ("inject sermorelin") rather than a vague reminder. Pair the injection with an existing nightly habit (brushing teeth, setting a morning alarm) to build an automatic cue-response loop.
For travel, keep reconstituted sermorelin refrigerated at 2 to 8 degrees Celsius. A standard insulin travel cooler with gel packs maintains temperature for 12 to 24 hours. TSA and most international equivalents permit prescription injectable medications with accompanying documentation. Carry the pharmacy label or a letter from your prescriber. If your vial reaches room temperature for more than 4 hours, discard it and use a fresh vial upon arrival. Sermorelin's peptide bonds degrade faster outside refrigeration, and a partially degraded dose may produce no meaningful GH response.
If you travel across time zones, adjust your injection to local bedtime on the first night. Do not inject twice in one calendar day to "cover" both time zones.
When to Contact Your Prescriber About Missed Doses
A single missed dose requires no clinical intervention. Notify your prescriber if any of the following apply.
You have missed three or more consecutive doses for any reason. Your provider may want to check IGF-1 levels 7 to 14 days after you resume dosing to confirm your axis has re-engaged.
You are consistently missing two or more doses per week. Adherence below 70% to 80% of prescribed doses significantly reduces the likelihood of achieving a therapeutic IGF-1 response. Dr. Richard Walker, whose 1990 pediatric sermorelin trial established much of the early efficacy data, noted that "the growth response to sermorelin is directly related to the consistency of administration" [7]. Adult data follow the same pattern.
You accidentally injected a double dose. A single double dose is unlikely to cause harm, but may produce transient side effects including facial flushing, headache, or injection-site irritation. Report these to your prescriber so they can document the event and adjust monitoring if needed.
You notice a sustained decline in the subjective benefits you had been experiencing (sleep quality, body composition changes, recovery time). This may reflect a dosing consistency problem or a need for dose adjustment. The Endocrine Society recommends titrating GH-axis therapies based on clinical response and IGF-1 levels rather than fixed dosing [5]. Your prescriber needs accurate adherence data to make that titration decision.
Sermorelin vs. Exogenous GH: Why Missed-Dose Rules Differ
Patients who have previously used recombinant GH (somatropin) sometimes apply those missed-dose habits to sermorelin. The pharmacology is different enough that the rules do not translate directly.
Somatropin has a half-life of 2 to 3 hours and produces a dose-dependent rise in serum GH that your body then clears over roughly 12 hours. Missing a somatropin dose means your serum GH drops to near zero (in patients with severe GH deficiency) until the next injection. Some somatropin prescribing information permits taking a missed dose within a few hours if the patient remembers in time.
Sermorelin's 10- to 20-minute half-life means the peptide itself is gone from circulation well before you would notice you missed it. But the GH pulse it triggers lasts 1 to 2 hours, and your pituitary continues producing smaller baseline pulses overnight regardless. You never reach "zero GH" the way a severe-GHD patient on somatropin might. This is one of the reasons some clinicians, including those at the American Association of Clinical Endocrinology (AACE), consider secretagogue therapy a gentler approach to GH-axis support [12].
The practical difference: with somatropin, a missed dose creates a true pharmacologic gap. With sermorelin, a missed dose reduces pulse amplitude but does not eliminate GH output. This makes sermorelin's missed-dose protocol simpler. Skip it, move on, and inject at your regular time tomorrow night.
Frequently asked questions
›What should I do if I miss my sermorelin injection?
›Can I take sermorelin in the morning if I missed it at bedtime?
›How does sermorelin work?
›Will one missed sermorelin dose affect my IGF-1 levels?
›Is it dangerous to accidentally take a double dose of sermorelin?
›Why is sermorelin injected at bedtime?
›What is the half-life of sermorelin?
›How many doses can I miss before it matters clinically?
›Should I adjust my sermorelin dose when traveling across time zones?
›Does food affect sermorelin absorption?
›How is missing a sermorelin dose different from missing a somatropin dose?
›Can I take sermorelin every other day instead of daily?
References
- Mayo KE, et al. The growth-hormone-releasing hormone receptor: signal transduction, clinical significance, and therapeutic potential. Endocr Rev. 1995;16(1):3-21. https://pubmed.ncbi.nlm.nih.gov/7758430/
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. https://pubmed.ncbi.nlm.nih.gov/18031173/
- Frohman LA, Downs TR, Chomczynski P. Regulation of growth hormone secretion. Front Neuroendocrinol. 1992;13(4):344-405. https://pubmed.ncbi.nlm.nih.gov/1281124/
- Van Cauter E, Plat L. Physiology of growth hormone secretion during sleep. J Pediatr. 1996;128(5 Pt 2):S32-37. https://pubmed.ncbi.nlm.nih.gov/8627466/
- Molitch ME, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587-1609. https://pubmed.ncbi.nlm.nih.gov/21602453/
- Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717-797. https://pubmed.ncbi.nlm.nih.gov/9861545/
- Walker RF, et al. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/2106646/
- Hartman ML, et al. Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal men. J Clin Endocrinol Metab. 1992;74(4):757-765. https://pubmed.ncbi.nlm.nih.gov/1548337/
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Baxter RC. Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res. 1994;42(4-5):140-144. https://pubmed.ncbi.nlm.nih.gov/7532612/
- Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab. 1991;73(5):1081-1088. https://pubmed.ncbi.nlm.nih.gov/1939523/
- American Association of Clinical Endocrinology. Clinical practice guidelines for growth hormone use in growth hormone-deficient adults and transition patients. Endocr Pract. 2019;25(11):1191-1232. https://pubmed.ncbi.nlm.nih.gov/31612120/